Compile Data Set for Download or QSAR

Found 9 hits of ic50 for monomerid = 311600   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Proto-oncogene tyrosine-protein kinase receptor Ret (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...				Citation and Details BindingDB Entry DOI: 10.7270/Q2280BR0
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.900	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.900	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804M] (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.900	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...				Citation and Details BindingDB Entry DOI: 10.7270/Q2280BR0
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804M] (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.90	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description RET (V804M) (i.e., RET with V804M mutation) kinase activity was measured using purified recombinant human RET (V804M) protein purchased from Eurofins...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804M] (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.90	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311600 (Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2cn(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H21N5OS/c1-19(7-8-19)24-9-14(15-16(20)21-11-22-17(15)24)18(25)23-13-5-3-12(4-6-13)10-26-2/h3-6,9,11H,7-8,10H2,1-2H3,(H,23,25)(H2,20,21,22)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.90	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...				Citation and Details BindingDB Entry DOI: 10.7270/Q2280BR0
					More data for this Ligand-Target Pair